News

A reflection on 2024's dermatology advancements, from FDA approvals to expert insights, setting the stage for another transformative year in 2025.

Graber spoke with Dermatology Times to share the top clinical pearls and key takeaways from the recent meetings.

With high clinician and participant satisfaction ratings, VYC-17.5 L was found to be safe and effective in reducing the appearance of marionette lines.

Catch up on exclusive interviews with Shanna Miranti, MPAS, PA-C; Renata Block, MMS, PA-C; Jane Mast, PhD, DMSc, MPAS; PA-C; Sara Wilchowski, DMSc, MPAS, PA-C; and Michael Rubio, PA-C, from the 2024 SDPA Fall Conference.

Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.

In case you missed it, this week we had news about the FDA-approval of Yesintek for psoriasis treatment, APG777 clinical trial updates, our inaugural Horizons in Advanced Practice meeting, and more.

Certain dermoscopic features in cutaneous warts may be associated with a favorable cryotherapy response.

Researchers found patients reporting greater disease burden and lower HRQoL are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.

Researchers stated that therapy represents a “valuable nonpharmacological intervention that offers an innovative therapeutic alternative” for acne treatment.

A study using proteome-wide association techniques identified novel protein biomarkers for atopic dermatitis.

The algorithm demonstrated 81% accuracy, promising fast, reliable, and reproducible assessments for patients. 

Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.

Although all observed treatments showed efficacy, the 30 mg dosage of upadacitinib was most successful in relieving itch for atopic dermatitis patients.

Investigating podiatry students' diagnostic accuracy and reasoning for dermatological lesions across skin tones using a mixed-method research approach.

Diarrhea, nausea, and headache were the most frequently reported adverse events in psoriasis patients.

The exclusive event brought together physician assistants and nurse practitioners from across the country to review atopic dermatitis and psoriasis patient cases.

Researchers found patients treated with risankizumab had higher rates of skin clearance and greater improvement than those treated with deucravacitinib.

The FDA recently approved Yesintek for treating psoriasis, psoriatic arthritis, and IBD, with a 2025 launch expected.

Promising new data was released along with a timeline of upcoming studies evaluating potential combination therapies for atopic dermatitis.

Explore key insights and innovations in vitiligo from 2024, from treatment advances to patient-focused strategies.

LOV has unique clinical traits, epidemiology, and treatment responses compared to early-onset vitiligo, underscoring the need for a tailored management approach.

Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.

Regenerative methods such as cell therapy and platelet-rich plasma showed promising results in patient repigmentation.

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

Read more about acne treatment tips shared at the 2024 SDPA Fall Conference by experts such as Shanna Miranti, MPAS, PA-C, and Hilary Baldwin, MD.

A clinical trial and laboratory study assessed skin’s hydration, antioxidation, and wrinkle presence after treatment with cacao.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Ahead of 2025, Dermatology Times wants to know what conferences and meetings you plan to attend in early 2024. Share your thoughts with us by December 10.

Learn more about the in-depth topics covered in the November 2024 CHE digital supplement of Dermatology Times.

Hawkes highlighted how second-generation TYK2 inhibitors improve upon earlier oral therapies with greater efficacy and selectivity.